SRR5903549
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- GLYCOLYSIS+0.390
- MYC_TARGETS_V1+0.380
- PROTEIN_SECRETION+0.380
- G2M_CHECKPOINT+0.340
- E2F_TARGETS+0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- CHOLESTEROL_HOMEOSTASIS+0.280
- MTORC1_SIGNALING+0.270
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.610
- INTERFERON_GAMMA_RESPONSE-0.570
- ALLOGRAFT_REJECTION-0.510
- TNFA_SIGNALING_VIA_NFKB-0.490
- IL6_JAK_STAT3_SIGNALING-0.480
- IL2_STAT5_SIGNALING-0.390
- INFLAMMATORY_RESPONSE-0.350
- KRAS_SIGNALING_UP-0.290
- COMPLEMENT-0.240
- P53_PATHWAY-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518424 | — | C | 0.896 |
| 2 | SRR4296106 | — | cohortSQ1 | 0.865 |
| 3 | SRR6013505 | — | cohortA4 | 0.856 |
| 4 | TCGA-BT-A20N-01A-11R-A14Y-07 | — | — | 0.848 |
| 5 | MDT-AP-2956 | Med | Medulloblastoma | 0.842 |
| 6 | SRR25043616 | — | — | 0.839 |
| 7 | MNG1011 | — | — | 0.836 |
| 8 | TCGA-33-4586-01A-01R-1443-07 | — | cohortSQ2 | 0.834 |
| 9 | s0112311 | — | — | 0.832 |
| 10 | TCGA-AR-A1AS-01A-11R-A12P-07 | — | B | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |